Product Name :
Scriptaid
Description:
Scriptaid, also known as GCK 1026, is a HDAC inhibitor. Scriptaid protects against traumatic brain injury via modulation of PTEN and AKT pathway. Scriptaid improves in vitro development and nuclear reprogramming of somatic cell nuclear transfer bovine embryos. Scriptaid enhances the response of human tumor cells to radiation. Scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity.
CAS:
287383-59-9
Molecular Weight:
326.35
Formula:
C18H18N2O4
Chemical Name:
6-{2,4-dioxo-3-azatricyclo[7.3.1.0⁵,¹³]trideca-1(12),5,7,9(13),10-pentaen-3-yl}-N-hydroxyhexanamide
Smiles :
ONC(=O)CCCCCN1C(=O)C2C=CC=C3C=CC=C(C3=2)C1=O
InChiKey:
JTDYUFSDZATMKU-UHFFFAOYSA-N
InChi :
InChI=1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Scriptaid, also known as GCK 1026, is a HDAC inhibitor. Scriptaid protects against traumatic brain injury via modulation of PTEN and AKT pathway. Scriptaid improves in vitro development and nuclear reprogramming of somatic cell nuclear transfer bovine embryos. Scriptaid enhances the response of human tumor cells to radiation. Scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity.{{Aflibercept} web|{Aflibercept} Protein Tyrosine Kinase/RTK|{Aflibercept} Protocol|{Aflibercept} Description|{Aflibercept} supplier|{Aflibercept} Epigenetic Reader Domain} |Product information|CAS Number: 287383-59-9|Molecular Weight: 326.{{Romosozumab} medchemexpress|{Romosozumab} Purity & Documentation|{Romosozumab} In stock|{Romosozumab} manufacturer|{Romosozumab} Cancer} 35|Formula: C18H18N2O4|Chemical Name: 6-{2,4-dioxo-3-azatricyclo[7.PMID:24507727 3.1.0⁵,¹³]trideca-1(12),5,7,9(13),10-pentaen-3-yl}-N-hydroxyhexanamide|Smiles: ONC(=O)CCCCCN1C(=O)C2C=CC=C3C=CC=C(C3=2)C1=O|InChiKey: JTDYUFSDZATMKU-UHFFFAOYSA-N|InChi: InChI=1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
